Presenter's Information

Duk-Woo Park, MD

Country Korea (Republic of)
Specialty Interventional Cardiologist
  1. TAVR in Asia: Optimal TAVR Choice for Asian Patients with Small Annulus, Vessels, and Body Size
  2. Life Time Management: Future Coronary Access
  3. Renal Safety Issues in Dyslipidemia Treatment: Why is it Important?
  4. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The TAILORED-CHIP Trial
  5. DAPT Duration in Complex PCI: Unsettled or Already Established Issues?
  6. PCI Is Enough. - When PCI Should Not Be Standard Treatment
  7. Optimizing Follow-up Strategies Post Complex PCI: Answers from the POST-PCI Trial
  8. Celebration of LM PCI: Joy in Growth, Journeying Towards 25 Years
  9. TAVI Procedure Plan and How to Achieve Successful Results
  10. Make It Simple : TAVR Antithrombotics
  11. Optimal Duration of Antiplatelet Therapy Following Left Main and Bifurcation PCI
  12. FATE-MAIN Trial
  13. TAILRORED-CHIP Trial
  14. Anticoagulation vs. Antiplatelet After TAVR: ADAPT-TAVR Trial
  15. Eagle's Eye View: How to Get Patients on a Statin Timely and Keep Them on It
  16. SAPIEN: Simpler and More Sophisticated (X4 and ALLIANCE)
  17. Insight from All Data of Left Main Revascularization (MAINCOMPARE, SYNTAX, PRECOMBAT, NOBLE, EXCEL)
  18. Edoxaban vs. DAPT for Valve Thrombosis and Cerebral Thromboembolism After TAVR: Deep-Dive into ADAPT-TAVR Trial
  19. Case 1. Left Main Disease
  20. DM and Triple Vessel Disease; Old Evidence and Next New Trials?
  21. My Approach to Left Main Coronary Disease - Master\'s Skill Secret
  22. LM Revascularization 2022: Guidelines and Concept Change
  23. Long-Term Valve Durability Issues and Optimal Decision-Making: TAVR or SAVR, Mechanical or Bioprosthetic?
  24. Key Message from the ADAPT-TAVR Trial: What We Learned?
  25. Leaflet Thrombosis, Is It Clinically Relevant?
  26. Racial Disparities in TAVR: Similarities and Differences
  27. Clinical Impact of Patient-Prosthesis Mismatch After TAVR
  28. Pragmatic Antithrombotic Strategies According to Bleeding and Ischemic Risk
  29. Two Road Diverged in a Cath Lab: PCI vs CABG in Complex PCI
  30. How to Optimize Sapien 3 Implantation for Future Management: FCA, Bicuspid, ViV, Low risk AS
  31. What Is Your Choice for Adherance Hypertensive Patients with Dyslipidemia?
  32. Escalation and De-Escalation Strategy for CHIP-PCI Patients: The Temporal Tuning in the TAILORED-CHIP Trial
  33. 10-Year Final Report of PRECOMBAT Trial: Deep-Dive
  34. My Challenging LM PCI Case of the Year
  35. East-Asian Paradox for Antithrombotics: Theory, Evidence and Next Strategy
  36. [Master\'s Keynote Lecture] Hand Down a Secret of Left Main PCI
  37. Antithrombotic and Antiplatelet Choice in Complex PCI
  38. Integrated Use of Imaging and Physiology in Left Main PCI
  39. Optimal Antithrombotics After TAVR
  40. Current Status of TAVR in Korea and US: TP-TAVR Registry
  41. TAVR Will Be a Standard Treatment for All Patients with Aortic Stenosis
  42. Balloon-Expandable SAPIEN 3 Valve
  43. Bifurcation PCI: Data, Evidence, and Guidelines
  44. Impact of Severe Coronary Artery Calcification on PCI Outcomes
  45. Optimal Antithrombotics After TAVR: Ongoing Trials
  46. OCT Versus IVUS for Guiding PCI: Current Evidences and Ongoing OCTIVUS Trial
  47. 10-Year Follow-Up of MAIN-COMPARE Registry and Substudies
  48. Anticoagulation for TAVR: GALILEO, and Yet It Moves.
  49. LM Bifurcation
  50. East-Asian Paradox: How to Optimize P2Y12 Inhibitors for Asians?
  51. How To Do Successful Registry Studies?
  52. Bifurcation PCI 2019: What Are Novel Changes for Technique or Concept?
  53. Highlighting 20 years of CV Protection with Lipitor
  54. PCI in Post-TAVR Patients: Beyond the Barrier
  55. Severe Coronary Calcification: Predictors, Managing Strategy, and Outcomes
  56. Integrated Use of FFR and IVUS in Non-LM Bifurcation PCI
  57. Clinical Impact of Periprocedural Myocardial Injury After TAVR
  58. Optimal Antithrombotic Therapy and Ongoing Clinical Trials
  59. Mainstream of TAVR: Minimalist Approach
  60. Permanent Pacemaker and Para-valvular Leakage: How to Avoid?
  61. Minimalist TAVR with Edwards SAPIEN 3 Valve
  62. Time to Consider Different P2Y12 Strategy for Complex PCI/CHIP Patients: From OPTIMA to TAILORED-PCI Trial
  63. Ture Distal Left Main PCI (Medina 1,1,1 or 1,0,1) Contemporary Strategy: Provisional vs. Complex
  64. Metallic DES Are All Equivalent!
  65. TAVR in Asia: Current Challenges and Future Direction
  66. Comparative Outcomes of Contemporary DES in Real-World: Is There Difference?
  67. EBC-MAIN Like Analysis Using the Largest Real-World Left Main Database
  68. Valve Thrombosis, Durability and Ongoing Antithrombotic Trials for TAVR
  69. OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients
  70. Top 10 Tips on Bifurcation PCI
  71. Heavily Calcified Lesion: Rotational Atherectomy and Others
  72. Keynote Lecture on Bifurcation PCI: Expert\'s Concept and Technique
  73. TAVR - Moving to Lower Risk: STS or Age Per Se?
  74. Standard vs. Minimalist TAVR: When and How to Change?
  75. [Taped Case] TAVR with Sapien
  76. CTEPH; Diagnosis & Treatment
  77. All Contemporary DES Comparison; Data from Real-World Registry (IRIS-DES)
  78. Trends and Outcomes of Non-LM and LM Bifurcation PCI
  79. How Do I Choose Sapien 3, Evolut R or Lotus in My Practice?
  80. Long-Term Durability Issue of TAVR; Uncertainty or Would Be OK
  81. Contemporary Bifurcation PCI; How Advance over Time?
  82. Generalizability of EXCEL and NOBLE; Comparison with IRIS-MAIN Registry
  83. Where to Go? - Comparative Analysis: BMS, DES vs. BVS / - The Next Step: BVS in Challenging Lesions
  84. Can Different DES Make a Different Outcome?
  85. Future in Transcatheter Heart Valve Treatment
  86. SYNERGY : Latest Experience from Korea
  87. Growing Importance of Evidence in the Management of High CV Risk Patients
  88. How Much Promising BRS in Real-Practice PCI?; Updated Real-World Experience and Registry Data
  89. Bifurcation PCI Summary; Technique or Concept?
  90. BRS in Left Main PCI: Clinical Data and Experience
  91. DES Thrombosis and Restenosis: Still Problematic in Current Real-World with Updated DES
  92. Effect of Statin Therapy on Cardiovascular Outcome in Dyslipidemic Patients with CKD
  93. BVS: They Will Replace Metallic DES?
  94. Comparative Outcomes of New-Generation DES: IRIS-DES
  95. Can BVS Replace the Metal Stent?: Current Status and Future Perspective
  96. Shifting the Paradigm for Lipid Management: Pathways in Achieving Improved ASCVD Outcomes
  97. RDN; Indications & Evidence and Future
  98. Use of a Point-of-Care Platelet Function Assay to Improve the Prediction of Atherothrombotic Events after DES Implantation: ASAN-VerifyNow Registry
  99. Long-Term Outcomes After Stenting Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Disease: 10-Year Results of Bare-Metal Stents and 5-Year Results of Drug-Eluting Stents From the ASAN–MAIN (ASAN Medical Center–Left MAIN Revascularization) Registry
  100. AMC Experience of the Intervention for the Structural Heart Disease
  101. Early DES - What Did We Learn - Updates from the ZEST Trial
  102. Alternative and Next Antiplatelet Therapy Beyond ADP Blocker
  103. Seeing Is Believing. IVUS Is A Mandatory in All Patients!
  104. DES vs. CABG for Multivessel Disease: Same or Different Interpretation from Registry to RCT
  105. Use of VH-Findings as Surrogate Marker for Anti-Atherosclerotic Drug
  106. Wrapping Up Current Clinical Trials and Future Study Program
  107. VH AMC Clinical Experience
  108. Meta-Analysis of 3,900 Patients with Left Main Disease Intervention (BMS vs DES vs CABG)
  109. Impact of DES on Diabetes Mellitus in Long Coronary Lesion
Conference Slides
Category